Bio-Path Holdings Inc (BPTH)

0.39
0.04 12.46
NASDAQ : Health Care
Prev Close 0.34
Open 0.34
Day Low/High 0.33 / 0.42
52 Wk Low/High 1.00 / 3.19
Volume 448.48K
Avg Volume 427.80K
Exchange NASDAQ
Shares Outstanding 100.06M
Market Cap 38.02M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bio-Path Holdings Receives Notice Of Allowance For Key U.S. Composition Of Matter Patent

Bio-Path Holdings Receives Notice Of Allowance For Key U.S. Composition Of Matter Patent

Further Protects Company's Proprietary Liposomal Delivery and Antisense Technology

Bio-Path Holdings Reports First Quarter 2017 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Presents Results Showing Potential Of BP1002 As Treatment For Aggressive Non-Hodgkin's Lymphoma

- In Vivo and Preclinical Data Presented at AACR Annual Meeting -

Bio-Path Holdings Reports Full Year 2016 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Appoints Dr. Craig Hooper To Scientific Advisory Board

Renowned neuroimmunology researcher joins SAB to advance DNAbilize™ technology in glioblastoma

Short Interest In Bio-Path Holdings Expands By 23.3%

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 544,221 share increase in total short interest for Bio-Path Holdings, Inc. , to 2,876,240, an increase of 23.34% since 01/13/2017.

Bio-Path Holdings Reports Third Quarter 2016 Financial Results

Bio-Path Holdings Reports Third Quarter 2016 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Reports Second Quarter 2016 Financial Results

Bio-Path Holdings Reports Second Quarter 2016 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Announces Collaboration With Thomas Jefferson University For Systemic Antisense Immunotherapy Treatment For Brain Cancer

Bio-Path Holdings Announces Collaboration With Thomas Jefferson University For Systemic Antisense Immunotherapy Treatment For Brain Cancer

Sponsored Research Agreement will Evaluate DNAbilize™ Technology as a Cancer Vaccine to Activate Patients' Immune Systems to Fight Cancer